|
| Press Releases |
|
 |
|
| Friday, July 7, 2023 |
|
|
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI more info >> |
|
| Friday, June 30, 2023 |
|
|
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced |
| Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement. more info >> |
|
| Thursday, June 22, 2023 |
|
|
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo. more info >> |
|
| Monday, June 12, 2023 |
|
|
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD). more info >> |
|
| Thursday, June 8, 2023 |
|
|
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea |
| This application is the first application for lecanemab in Asia outside of Japan and China. Eisai plans to submit additional applications in other Asian countries. more info >> |
|
| Friday, June 2, 2023 |
|
|
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting |
| Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States. more info >> |
|
| Friday, May 26, 2023 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
| These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502). more info >> |
|
| Thursday, May 25, 2023 |
|
|
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria |
| Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ("GHIT Fund") to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027. more info >> |
|
| Wednesday, May 24, 2023 |
|
|
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6. more info >> |
|
| Saturday, May 20, 2023 |
|
|
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Waterloo Startup Axibo AI Secures $12M to Pioneer 'Made in Canada' Humanoids
Apr 23, 2025 21:00 HKT/SGT
|
|
|
Batch Bicycles and Hyatt Place Zhuhai jointly organized An Exhalating Cycling Event in Macau 
Apr 23, 2025 19:02 HKT/SGT
|
|
|
EdgePoint Towers advances renewable energy integration in telecommunications with first solar hybrid deployment
Apr 23, 2025 14:00 HKT/SGT
|
|
|
Fujitsu expands strategic collaboration with Supermicro to offer total generative AI platform
Apr 23, 2025 11:55 JST
|
|
|
Furuya Metal and Asahi Kasei Embark on Demonstration Trial Regarding Recycling of Metals for Chlor-alkali Electrolysis Cells and Electrodes
Apr 23, 2025 11:00 JST
|
|
|
Earth Day Special: foundit Report Reveals 27% Surge in Green Jobs as Singapore Accelerates Sustainability Push
Apr 23, 2025 09:00 HKT/SGT
|
|
|
2025 U.S. Open Polo Championship Final Concludes American High-Goal Season, Supported by U.S. Polo Assn.
Apr 22, 2025 19:00 HKT/SGT
|
|
|
A Strategic Event for HR Leaders and Experts to Drive Transformation in the Saudi Workforce
Apr 22, 2025 16:40 HKT/SGT
|
|
|
Under the patronage of Maktoum bin Mohammed DIFC to host 3rd edition of Dubai FinTech Summit on 12-13 May 2025
Apr 22, 2025 16:00 HKT/SGT
|
|
|
New Trading Bot Pivozon Targets Gold Traders Using Hourly Chart Strategies
Apr 22, 2025 15:30 HKT/SGT
|
|
|
A Decade of Olympus India's Commitment to Community Welfare
Apr 22, 2025 13:00 JST
|
|
|
Meerkat ($MERK) introduces utility-focused meme ecosystem with staking, gaming, and AI features
Apr 22, 2025 11:00 HKT/SGT
|
|
|
Fujitsu and RIKEN develop world-leading 256-qubit superconducting quantum computer
Apr 22, 2025 11:37 JST
|
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange
Apr 22, 2025 10:16 HKT/SGT
|
|
|
CIRC: Attained a New High in Fiscal Year 2024
Apr 22, 2025 09:52 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
